Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease
Ankit K. Desai(Duke Medical Center), Priya S. Kishnani(Duke Medical Center), Stephanie DeArmey(Duke Medical Center), Molly McPheron(Riley Hospital for Children), Damara Ortiz(Children's Hospital of Pittsburgh), Jennifer Hamm(East Tennessee Children's Hospital), Rossana Sanchez Russo(Emory University), Eleanor Rodriguez-Rassi(Duke Medical Center), Sarah P. Young(Duke Medical Center), Irene J. Chang(Seattle Children's Hospital), Suhag Parikh(Emory University), David Kronn(New York Medical College), Holly Lydigsen(University of Tennessee Health Science Center)
Cited by 1
Related Papers
Glycogen Storage Disease Type III diagnosis and management guidelines
|Genetics in Medicine|2010|305
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
|Genetics in Medicine|2009|292
Homozygous Mutations in CSF1R Cause a Pediatric-Onset Leukoencephalopathy and Can Result in Congenital Absence of Microglia
|The American Journal of Human Genetics|2019|263
Schwannomatosis
|Neurology|1996|244